DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. lowered its stake in DexCom, Inc. (NASDAQ:DXCM) by 99.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,515 shares of the medical device company’s stock after selling 1,204,600 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in DexCom were worth $273,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in DXCM. Townsquare Capital LLC raised its stake in DexCom by 43.6% in the third quarter. Townsquare Capital LLC now owns 9,568 shares of the medical device company’s stock valued at $641,000 after buying an additional 2,905 shares in the last quarter. Public Sector Pension Investment Board raised its position in shares of DexCom by 5.9% during the 3rd quarter. Public Sector Pension Investment Board now owns 17,842 shares of the medical device company’s stock worth $1,196,000 after acquiring an additional 1,000 shares in the last quarter. Captrust Financial Advisors lifted its stake in DexCom by 4.6% during the third quarter. Captrust Financial Advisors now owns 23,051 shares of the medical device company’s stock worth $1,545,000 after purchasing an additional 1,022 shares during the last quarter. Erste Asset Management GmbH acquired a new position in DexCom in the third quarter valued at approximately $694,000. Finally, Benjamin Edwards Inc. purchased a new position in DexCom in the third quarter valued at approximately $652,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 105,009 shares of company stock worth $8,044,178. 0.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Citigroup increased their target price on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Cfra Research upgraded DexCom to a “hold” rating in a research report on Friday, March 21st. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Canaccord Genuity Group raised their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Finally, Morgan Stanley boosted their price objective on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Trading Up 1.2 %

Shares of DexCom stock opened at $68.14 on Thursday. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The firm has a market cap of $26.63 billion, a price-to-earnings ratio of 47.65, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $141.99. The company’s 50-day simple moving average is $81.24 and its 200-day simple moving average is $77.04.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.